

Supplementary data for

NOVEL CLASS OF FUNCIONALIZED IONIC LIQUIDS WITH GRAFTED CMPO-MOIETIES FOR ACTINIDES AND RARE-EARTH ELEMENTS RECOVERY.

I.L. Odinets, E.V. Sharova, O.I.Artyshin, K.A. Lyssenko, Yu.V. Nelyubina,
G.V.Myasoedova, N.P.Molochnikova, E.A.Zakharchenro

1.1. Experimental details

2-(Diphenylphosphinyl)-N-[3-(1*H*-imidazol-1-yl)propyl]-acetamide (3). A mixture of ethyl(diphenylphosphoryl)acetate (4.6 g, 0.016 mol) and 3-(1*H*-imidazol-1-yl)-1-propanamine (2.8 g, 0.023 mol) in 5 mL of anhydrous EtOH was heated in a sealed tube in a boiling water bath for 72 h. The tube was opened, the solvent was removed *in vacuo*, and the residue was recrystallized from EtOAc-EtOH (10:1) to give **3** as a white solid; yield: 4.7 g (81%); mp 145-146 °C (EtOAc-EtOH). IR (cm⁻¹): 1438 (ν_{CH₂}), 1180 (ν_{P=O}), 1661 (ν_{C=O}), 3263, 1546 (ν_{NH}). ¹H NMR (400 MHz, CDCl₃, ppm, J/Hz): 1.83 (q, 2H, CH₂CH₂NHC(O), ³J_{H-H}=6.6); 3.20 (appeared qv, 2H, CH₂NHC(O), ³J_{H-H}=6.4); 3.31 (d, 2H, PCH₂, ²J_{P-H}=12.4); 3.69 (t, 2H, CH₂CH₂CH₂NHC(O), ³J_{H-H}=7.1); 6.79 (br. s, 1H, C⁵H in Im); 7.00 (br. s, 1H, C⁴H in Im); 7.46 (br. s, 1H, NH); 7.47-7.53 (m, 4H, *m*-C₆H₅P); 7.54-7.60 (m, 2H, *p*-C₆H₅P); 7.70-7.78 (m, 4H, *o*-C₆H₅P); 7.32 (br. s, 1H, N=CH-N). ³¹P NMR (162 MHz, CDCl₃, ppm): 30.41 ppm. ¹³C NMR (75.47 MHz, CDCl₃): δ 30.32 (CH₂CH₂N), 35.98 (NHCH₂), 38.41 (d, PCH₂, ¹J_{PC}=60.9 Hz), 43.47 (N_{Im}-CH₂), 118.46 (C⁴ (Im)), 128.38 (d, *m*-C in C₆H₅, ³J_{PC}= 12.1 Hz), 128.72 (C⁵ (Im)), 130.29 (d, *o*-C in C₆H₅, ²J_{PC}=9.9 Hz), 131.16 (d, ipso-C in C₆H₅, ¹J_{PC}=103.2 Hz), 131.97 (*p*-C in C₆H₅), 136.71 (C² (Im)), 164.59 (d, C(O), ²J_{PC}=4.9 Hz). Anal. Calcd for C₂₀H₂₂N₃O₂P: C, 65.39; H, 6.04; N, 11.44; P, 8.43. Found: C, 65.24; H, 5.86; N, 11.39; P, 8.13.

Table S1. Selected bond lengths and angles in crystals of **4d** and **6c**.

Lengths, Å	4d	6c	Angles, °	4d	6c
P(1)-O(1)	1.4907(17)	1.4944(14)	O(1)P(1)C(10)	112.34(11)	116.22(9)
N(1)-C(2)	1.326(3)	1.322(2)	N(1)C(2)N(3)	108.3(2)	109.19(18)
C(2)-N(3)	1.332(3)	1.325(2)	C(2)N(3)C(4)	108.9(2)	108.19(17)
N(3)-C(4)	1.371(3)	1.376(2)	N(3)C(4)C(5)	107.1(2)	106.99(18)
C(4)-C(5)	1.351(3)	1.349(3)	C(4)C(5)N(1)	106.9(2)	107.23(17)
C(5)-N(1)	1.378(3)	1.371(2)	C(5)N(1)C(2)	108.85(19)	108.40(17)
N(1)-C(6)	1.469(3)	1.473(2)	C(2)N(1)C(6)	125.5(2)	124.16(17)
C(6)-C(7)	1.521(4)	1.530(3)	N(1)C(6)C(7)	110.6(2)	110.96(16)
C(7)-C(8)	1.518(3)	1.522(3)	C(6)C(7)C(8)	114.0(2)	114.72(16)
N(4)-C(8)	1.453(3)	1.450(2)	C(7)C(8)N(4)	110.5(2)	112.04(16)
N(4)-C(9)	1.336(3)	1.346(2)	C(8)N(4)C(9)	123.5(2)	123.76(16)
C(9)-O(2)	1.230(3)	1.238(2)	O(2)C(9)N(4)	123.8(2)	123.65(18)

Table S2. Crystal data and structure refinement parameters for **4d** and **6c**.

Compound	4d	6c
Empirical formula	C ₆₀ H ₈₆ Br ₂ Cl ₆ N ₆ O ₅ P ₂	C ₂₆ H ₃₅ F ₆ N ₃ O ₂ P ₂
Formula weight	1405.81	597.51
Crystal colour, habit	colorless, prism	colorless, needle
Crystal size (mm)	0.18 × 0.20 × 0.25	0.08 × 0.10 × 0.45
Crystal system	Orthorhombic	Triclinic
Space group	Pbca	P-1
<i>a</i> (Å)	23.9357(16)	5.9341(9)
<i>b</i> (Å)	11.7625(8)	15.819(3)
<i>c</i> (Å)	25.1174(17)	16.393(3)
α (°)	–	65.857(3)
β (°)	–	88.250(4)
γ (°)	–	80.353(4)
<i>V</i> (Å ³)	7071.6(8)	1383.1(4)
<i>Z</i> (<i>Z</i>)	4(0.5)	2(1)
<i>F</i> (000)	2920	624
<i>D</i> _{calc} (g cm ⁻³)	1.320	1.435
Linear absorption, μ (cm ⁻¹)	14.66	2.28
$2\theta_{max}$ (°)	58	54
Completeness of dataset (%)	99.9	98.0
Reflections measured	82400	8923
Independent reflections	9385 [R _{int} = 0.0622]	5935 [R _{int} = 0.0284]
Observed reflections [<i>I</i> > 2σ(<i>I</i>)]	6976	3936
Parameters	378	356
Final <i>R</i> (<i>F</i> _{hkl}): <i>R</i> ₁	0.0385	0.0403
<i>wR</i> ₂	0.1233	0.0677
GOF	1.007	1.004
$\Delta\rho_{max}, \Delta\rho_{min}$ (e Å ⁻³)	0.808, -0.602	0.365, -0.391

Spectroscopy of compounds





Fig S1. The ³¹P spectrum for ligand **4d**





Fig S2. The ^{31}P spectrum for ligand **4f**





Fig S3. The ^{31}P spectrum for ligand **5d**





Fig S4. The ³¹P spectrum for ligand **6b**




Fig S5. The ¹⁹F spectrum for ligand **6b**





Fig S6. The ³¹P spectrum for ligand **6c**




Fig S7. The ¹⁹F spectrum for ligand **6c**





Fig S8. The ³¹P spectrum for ligand **6f**




Fig S9. The ¹⁹F spectrum for ligand **6f**





Fig S10. The ¹⁹F spectrum for complex **7a**